Over the past 12 months, 8 insiders at Kiniksa Pharmaceuticals International, plc filed 48 open-market SEC Form 4 transactions on KNSA: 0 purchases worth $0 and 48 sales worth $45.5M. Insiders have been net sellers over this period. The most recent filing was on Mar 9, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 9, 26 | Mark RagosaCHIEF FINANCIAL OFFICER | SELL | 18.7K | $46.24 | $867K |
| Mar 2, 26 | John F. PaoliniCHIEF MEDICAL OFFICER | SELL | 22.2K | $45.92 | $997K |
| Feb 12, 26 | Barry D QuartDirector | SELL | 2.7K | $45.00 | $121K |
| Feb 10, 26 | Barry D QuartDirector | SELL | 110 | $45.00 | $5K |
| Feb 9, 26 | Mark RagosaCHIEF FINANCIAL OFFICER | SELL | 9.1K | $43.72 | $391K |
| Feb 4, 26 | Barry D QuartDirector | SELL | 2.6K | $45.02 | $117K |
| Feb 3, 26 | Barry D QuartDirector | SELL | 12.5K | $45.27 | $567K |
| Feb 2, 26 | Barry D QuartDirector | SELL | 830 | $45.00 | $37K |
| Jan 8, 26 | Mark RagosaCHIEF FINANCIAL OFFICER | SELL | 12.0K | $41.89 | $503K |
| Dec 15, 25 | Barry D QuartDirector | SELL | 20.1K | $41.51 | $836K |
| Dec 15, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 12.0K | $41.56 | $501K |
| Dec 8, 25 | Mark RagosaCHIEF FINANCIAL OFFICER | SELL | 42.8K | $41.49 | $1.8M |
| Nov 26, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 200 | $42.89 | $9K |
| Nov 17, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 11.8K | $41.30 | $488K |
| Nov 12, 25 | Mark RagosaCHIEF FINANCIAL OFFICER | SELL | 19.9K | $40.94 | $815K |
| Oct 31, 25 | John F. PaoliniCHIEF MEDICAL OFFICER | SELL | 82.5K | $37.14 | $3.1M |
| Oct 28, 25 | Mark RagosaCHIEF FINANCIAL OFFICER | SELL | 100 | $41.00 | $4K |
| Oct 22, 25 | Sanj K PatelCHAIRMAN & CEO | SELL | 97.4K | $38.83 | $3.8M |
| Oct 21, 25 | Sanj K PatelCHAIRMAN & CEO | SELL | 39.3K | $38.77 | $1.5M |
| Oct 20, 25 | Michael R MegnaCHIEF ACCOUNTING OFFICER | SELL | 37.3K | $39.31 | $1.4M |
| Oct 20, 25 | Sanj K PatelCHAIRMAN & CEO | SELL | 98.9K | $39.32 | $3.8M |
| Oct 14, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 11.8K | $37.99 | $445K |
| Sep 29, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 42.0K | $38.33 | $1.6M |
| Sep 15, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 16.0K | $37.00 | $585K |
| Sep 5, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 13.4K | $35.66 | $477K |
| Sep 4, 25 | Ross MoatCHIEF CORP. & COMM. OFFICER | SELL | 3.5K | $35.31 | $124K |
| Sep 4, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 85.3K | $35.52 | $3.0M |
| Sep 3, 25 | Michael R MegnaCHIEF ACCOUNTING OFFICER | SELL | 11.0K | $34.84 | $383K |
| Sep 3, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 15.1K | $35.50 | $536K |
| Aug 18, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 16.1K | $34.44 | $544K |
| Aug 14, 25 | Thomas MalleyDirector | SELL | 78.2K | $33.09 | $2.6M |
| Aug 13, 25 | Thomas MalleyDirector | SELL | 50.1K | $33.32 | $1.7M |
| Aug 12, 25 | Thomas MalleyDirector | SELL | 49.4K | $32.40 | $1.6M |
| Aug 6, 25 | John F. PaoliniCHIEF MEDICAL OFFICER | SELL | 29.3K | $32.55 | $955K |
| Aug 5, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 138.1K | $33.90 | $4.6M |
| Aug 4, 25 | Mark RagosaCHIEF FINANCIAL OFFICER | SELL | 18.9K | $32.89 | $621K |
| Aug 4, 25 | Michael R MegnaCHIEF ACCOUNTING OFFICER | SELL | 17.0K | $32.35 | $550K |
| Jul 14, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 18.9K | $28.72 | $543K |
| Jun 16, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 17.3K | $28.28 | $489K |
| Jun 11, 25 | Barry D QuartDirector | SELL | 12.3K | $30.39 | $375K |
| Jun 11, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 45.0K | $30.51 | $1.4M |
| Jun 10, 25 | Barry D QuartDirector | SELL | 8.2K | $30.36 | $249K |
| Jun 10, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 15.5K | $30.46 | $472K |
| Jun 9, 25 | Barry D QuartDirector | SELL | 6.9K | $30.26 | $209K |
| Jun 9, 25 | Eben TessariCHIEF OPERATING OFFICER | SELL | 10.3K | $30.38 | $313K |
| Jun 3, 25 | Michael R MegnaCHIEF ACCOUNTING OFFICER | SELL | 15.2K | $28.75 | $437K |
| Jun 3, 25 | Ross MoatCHIEF COMMERCIAL OFFICER | SELL | 27.6K | $29.02 | $801K |
| Jun 3, 25 | Mark RagosaCHIEF FINANCIAL OFFICER | SELL | 18.3K | $28.80 | $527K |
| May 28, 25 | Sanj K PatelCHAIRMAN & CEO | SELL | 62.1K | $27.33 | $1.7M |
| May 27, 25 | Sanj K PatelCHAIRMAN & CEO | SELL | 19.3K | $27.01 | $522K |
Over the past 12 months, insiders at Kiniksa Pharmaceuticals International, plc filed 0 open-market purchases worth $0 and 48 sales worth $45.5M on KNSA, which makes them net sellers over the period. The most recent Form 4 was filed on Mar 9, 26.
8 different insiders at Kiniksa Pharmaceuticals International, plc filed open-market SEC Form 4 transactions on KNSA over the last 12 months.
InsiderTape plots every KNSA insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Kiniksa Pharmaceuticals International, plc insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →